Madhavan Balachandran Sells 10,000 Shares of uniQure (NASDAQ:QURE) Stock

uniQure N.V. (NASDAQ:QURE) Director Madhavan Balachandran sold 10,000 shares of the business’s stock in a transaction dated Monday, June 15th. The stock was sold at an average price of $27.85, for a total value of $278,500.00. Following the transaction, the director directly owned 43,254 shares of the company’s stock, valued at approximately $1,204,623.90. The trade was a 18.78% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Madhavan Balachandran also recently made the following trade(s):

• On Thursday, June 11th, Madhavan Balachandran sold 1,993 shares of uniQure stock. The shares were sold at an average price of $27.06, for a total transaction of $53,930.58.

uniQure Trading Down 3.9%

Shares of uniQure stock opened at $46.29 on Friday. The firm’s 50 day moving average is $24.13 and its 200 day moving average is $22.03. The firm has a market capitalization of $2.92 billion, a PE ratio of -13.30 and a beta of 0.98. uniQure N.V. has a 1 year low of $8.73 and a 1 year high of $71.50. The company has a current ratio of 10.40, a quick ratio of 10.40 and a debt-to-equity ratio of 0.33.

uniQure (NASDAQ:QURE) last issued its quarterly earnings data on Tuesday, May 5th. The biotechnology company reported ($0.85) EPS for the quarter, beating the consensus estimate of ($0.88) by $0.03. uniQure had a negative net margin of 1,154.42% and a negative return on equity of 145.81%. The business had revenue of $3.56 million during the quarter, compared to the consensus estimate of $5.21 million. Equities research analysts forecast that uniQure N.V. will post -3.64 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several equities research analysts recently weighed in on the company. HC Wainwright reissued a “buy” rating on shares of uniQure in a report on Thursday. Wells Fargo & Company raised uniQure from an “equal weight” rating to an “overweight” rating and upped their target price for the stock from $15.00 to $60.00 in a report on Monday, March 9th. Mizuho upgraded uniQure from a “neutral” rating to an “outperform” rating and increased their target price for the company from $12.00 to $35.00 in a research report on Wednesday, March 11th. TD Cowen reissued a “buy” rating on shares of uniQure in a research note on Tuesday, March 3rd. Finally, Barclays upgraded uniQure from an “equal weight” rating to an “overweight” rating and boosted their price target for the stock from $25.00 to $65.00 in a report on Thursday. Twelve research analysts have rated the stock with a Buy rating, four have assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, uniQure has a consensus rating of “Moderate Buy” and a consensus target price of $58.92.

uniQure News Roundup

Here are the key news stories impacting uniQure this week:

• Positive Sentiment: FDA feedback now suggests uniQure can move ahead with a BLA submission for AMT-130 using existing mid-stage data, significantly improving the regulatory timeline. Reuters
• Positive Sentiment: Cantor Fitzgerald upgraded uniQure to Overweight and raised its price target, reflecting improved confidence in the company’s Huntington’s program. Seeking Alpha
• Positive Sentiment: Barclays also upgraded the stock and lifted its target, adding to the wave of bullish analyst sentiment after the FDA development. Benzinga
• Neutral Sentiment: There were insider sales disclosed this week, including transactions by directors and executives, but these appear to be routine filings and are being overshadowed by the FDA-driven rally.

Institutional Trading of uniQure

Several institutional investors have recently modified their holdings of the business. Jones Financial Companies Lllp raised its position in uniQure by 509.0% during the 3rd quarter. Jones Financial Companies Lllp now owns 609 shares of the biotechnology company’s stock worth $33,000 after purchasing an additional 509 shares during the last quarter. CIBC Private Wealth Group LLC acquired a new position in uniQure during the 3rd quarter worth about $50,000. Torren Management LLC bought a new stake in shares of uniQure in the 4th quarter valued at about $28,000. FNY Investment Advisers LLC grew its position in shares of uniQure by 76.7% in the 3rd quarter. FNY Investment Advisers LLC now owns 1,654 shares of the biotechnology company’s stock valued at $96,000 after buying an additional 718 shares during the last quarter. Finally, IFP Advisors Inc acquired a new stake in shares of uniQure in the fourth quarter valued at about $48,000. Institutional investors own 78.83% of the company’s stock.

uniQure Company Profile

uniQure N.V. is a biotechnology company focused on the development and commercialization of gene therapies for patients with severe medical needs. Using its proprietary adeno‐associated viral (AAV) vector platform, the company designs single‐dose treatments aimed at addressing the underlying genetic causes of disease rather than solely managing symptoms. Its most advanced program, Hemgenix® (etranacogene dezaparvovec), received regulatory approval in the United States and Europe for adult patients with hemophilia B, marking one of the first gene therapies for a bleeding disorder to reach the market.

Beyond hemophilia B, uniQure’s pipeline includes preclinical and clinical-stage candidates targeting rare and debilitating conditions such as aromatic l-amino acid decarboxylase (AADC) deficiency, Huntington’s disease, and Parkinson’s disease.